Depósito Digital de Documentos de la UAB Encontrados 4 registros  La búsqueda tardó 0.01 segundos. 
1.
10 p, 1.2 MB A randomised phase 2 study comparing different dose approaches of induction treatment of regorafenib in previously treated metastatic colorectal cancer patients (REARRANGE trial) / Argilés Martínez, Guillem ; Mulet, N. (Memorial Sloan Kettering Cancer Center) ; Valladares-Ayerbes, M. (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ; Viéitez, J.M. (Hospital Universitario Central de Asturias) ; Grávalos, Cristina (Hospital Universitario 12 de Octubre (Madrid)) ; García-Alfonso, P. (H. Gregorio Marañón) ; Santos, C. (ICO. H. Duran i Reynals) ; Tobeña, M. (Institut d'Investigació Biomèdica Sant Pau) ; García Paredes, B. (H. Universitario Clínico San Carlos) ; Benavides Orgaz, Manuel (Hospital Universitario Virgen de la Victoria (Màlaga, Andalusia)) ; Cano, M.T. (H. Universitario Reina Sofía) ; Loupakis, F. (IOV (Istituto oncologico Veneto)) ; Rodríguez-Garrote, M. (Instituto Ramón y Cajal de Investigación Sanitaria (Madrid)) ; Rivera, F. (Instituto de Investigación Marqués de Valdecilla) ; Goldberg, R.M. (West Virgina University Cancer Institute) ; Cremolini, Chiara (A. O. Universitaria Pisana) ; Bennouna, J. (CHU-Nante) ; Ciardiello, Fortunato ; Tabernero, Josep (Vall d'Hebron Institut d'Oncologia) ; Aranda, E. (H. Universitario Reina Sofía) ; Tabernero, J. (Memorial Sloan Kettering Cancer Center) ; Falcone, A. (Gustave Roussy) ; Goldberg, R. ; Argilés, None (Memorial Sloan Kettering Cancer Center) ; Tabernero, J. (Memorial Sloan Kettering Cancer Center) ; Mulet, N. (Memorial Sloan Kettering Cancer Center) ; Limón, M.L. (H. Virgen del Rocío) ; Valladares, M. (H. Virgen del Rocío) ; Jiménez, P. (H. Universitario Central de Asturias) ; Vieitez, J.M. (H. Universitario Central de Asturias) ; Grávalos, C. (H. 12 de Octubre) ; García-Alfonso, P. (H. Gregorio Marañón) ; Santos, C. (ICO. H. Duran i Reynals) ; Páez, David (Institut d'Investigació Biomèdica Sant Pau) ; Sastre Valera, Javier (H. Universitario Clínico San Carlos) ; García Paredes, B. (H. Universitario Clínico San Carlos) ; Benavides Orgaz, Manuel (Hospital Universitario Virgen de la Victoria (Màlaga, Andalusia)) ; Aranda, E. (H. Universitario Reina Sofía) ; Cano, M.T. (H. Universitario Reina Sofía) ; Loupakis, F. (IOV (Istituto oncologico Veneto)) ; Rguez Garrote, M. (H. Ramón y Cajal) ; Guillén, C. (H. Ramón y Cajal) ; Rivera, M.F. (H. Marqués de Valdecilla) ; Safont, J. (H. General Universitario) ; Hiret, S. (Institut de Cancérologie de l'Ouest) ; Bennouna, J. (CHU-Nante) ; Pannier, D. (Centre Oscar Lambret) ; Malka, D. (Gustave Roussy) ; Falcone, A. (Gustave Roussy) ; Cremolini, Chiara (A. O. Universitaria Pisana) ; Universitat Autònoma de Barcelona
Purpose: The purpose of this article is to evaluate the safety of two regorafenib dose-escalation approaches in refractory metastatic colorectal cancer (mCRC) patients. Patients and methods: Patients with mCRC and progression during or within 3 months following their last standard chemotherapy regimen were randomised to receive the approved dose of regorafenib of 160 mg QD (arm A) or 120 mg QD (arm B) administered as 3 weeks of treatment followed by 1 week off, or 160 mg QD 1 week on/1 week off (arm C). [...]
2022 - 10.1016/j.ejca.2022.09.037
European journal of cancer, Vol. 177 (december 2022) , p. 154-163  
2.
11 p, 877.0 KB Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma : Results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy / Zandberg, Dan P. (University of Pittsburgh Medical Center. Hillman Cancer Center) ; Algazi, Alain P. (University of California San Francisco Helen Diller Family Comprehensive Cancer Center) ; Jimeno, Antonio (Division of Medical Oncology. University of Colorado School of Medicine) ; Good, James S. (Institute of Head and Neck Studies and Education. Queen Elizabeth Hospital) ; Fayette, Jérôme (Clinical Oncology. Cancer Center Centre Léon Bérard. University of Lyon) ; Bouganim, Nathaniel (Department of Oncology. McGill University Health Centre) ; Ready, Neal E. (Duke University Medical Center) ; Clement, Paul M. (Department of Oncology. Leuven Cancer Institute) ; Even, Caroline (Institut Gustave Roussy (Villejuif, França)) ; Jang, Raymond W. (Princess Margaret Cancer Centre. University of Toronto) ; Wong, Stuart (Division of Hematology Oncology. Medical College of Wisconsin) ; Keilholz, Ulrich (Charité Comprehensive Cancer Center) ; Gilbert, Jill (Henry-Joyce Cancer Clinic) ; Fenton, Moon (The West Cancer Center. University of Tennessee Health Science Center) ; Braña, Irene (Vall d'Hebron Institut d'Oncologia) ; Henry, Stephanie (Department of Oncology-Hematology. Radiotherapy. and Nuclear Medicine. CHU UCL Namur) ; Remenar, Eva (National Institute of Oncology (Országos Onkológiai Intézet)) ; Papai, Zsuzsanna (State Health. Center Higatian Defanse Forses) ; Siu, Lillian L. (Princess Margaret Cancer Centre. University of Toronto) ; Jarkowski, Anthony (AstraZeneca) ; Armstrong, Jon M. (AstraZeneca) ; Asubonteng, Kobby (AstraZeneca) ; Fan, Jean (AstraZeneca) ; Melillo, Giovanni (AstraZeneca) ; Mesía, Ricard (Institut d'Investigació Biomèdica de Bellvitge) ; Universitat Autònoma de Barcelona
Background: Patients with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) progressing on platinum-based chemotherapy have poor prognoses and limited therapeutic options. Programmed cell death-1 (PD-1) and its ligand 1 (PD-L1) are frequently upregulated in HNSCC. [...]
2019 - 10.1016/j.ejca.2018.11.015
European journal of cancer, Vol. 107 (january 2019) , p. 142-152  
3.
7 p, 306.9 KB Genetic counselling and testing of susceptibility genes for therapeutic decision-making in breast cancer-an European consensus statement and expert recommendations / Singer, Christian. F. (Medical University of Vienna) ; Balmaña Gelpí, Judith (Vall d'Hebron Institut d'Oncologia) ; Bürki, Nicole. (University Hospital Basel (Basilea, Suïssa)) ; Delaloge, Suzette (Gustave Roussy) ; Filieri, M. E. (University Hospital of Modena) ; Gerdes, A. M. (University of Copenhagen) ; Grindedal, E. M. (Oslo University Hospital (Oslo, Noruega)) ; Han, Sileny (UZ Leuven) ; Johansson, Oskar. (Landspitali University Hospital (Reykjavík, Islàndia)) ; Kaufman, Bella. (Sheba Medical Center) ; Krajc, Mateja. (Institute of Oncology Ljubljana) ; Loman, Niklas. (Lund University Hospital) ; Olah, Edith. (National Institute of Oncology) ; Paluch-Shimon, Shani. (Shaare Zedek Medical Centre) ; Plavetic, Natalija Dedic (University of Zagreb) ; Pohlodek, Kamil. (Comenius University of Bratislava) ; Rhiem, Kerstin. (Uniklinik Köln (Colònia, Alemanya)) ; Teixeira, Manuel. (Portuguese Oncology Institute) ; Evans, D. Gareth. (University of Manchester) ; Universitat Autònoma de Barcelona
An international panel of experts representing 17 European countries and Israel convened to discuss current needs and future developments in BRCA testing and counselling and to issue consensus recommendations. [...]
2019 - 10.1016/j.ejca.2018.10.007
European journal of cancer, Vol. 106 (january 2019) , p. 54-60  
4.
12 p, 744.6 KB First-line panitumumab plus FOLFOX4 or FOLFIRI in colorectal cancer with multiple or unresectable liver metastases: A randomised, phase II trial (PLANET-TTD) / Carrato, Alfredo (Instituto Ramón y Cajal de Investigación Sanitaria (Madrid)) ; Abad, Albert (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Massuti, Bartomeu (Hospital General Universitario de Alicante (Alacant, País Valencià)) ; Grávalos, Cristina (Hospital Universitario 12 de Octubre (Madrid)) ; Escudero, Pilar (Hospital Clínico Universitario "Lozano Blesa" de Zaragoza) ; Longo Muñoz, Federico (Instituto Ramón y Cajal de Investigación Sanitaria (Madrid)) ; Manzano, José Luis (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Gómez, Auxiliadora (Instituto Maimónides de Investigación Biomédica de Córdoba) ; Safont, María José (Hospital General Universitario de Valencia) ; Gallego, Javier (Hospital General Universitario de Elche) ; García-Paredes, Beatriz (Hospital Clínico San Carlos (Madrid)) ; Pericay, Carles (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT)) ; Dueñas, Rosario (Complejo Hospitalario de Jaén) ; Rivera, Fernando (Hospital Universitario Marqués de Valdecilla (Santander, Cantabria)) ; Losa, Ferrán (Hospital General de l'Hospitalet) ; Valladares Ayerbes, Manuel (Complejo Hospitalario Universitario de A Coruña) ; González, Encarnación (Hospital Universitario Virgen de las Nieves (Granada)) ; Aranda, Enrique (Instituto Maimónides de Investigación Biomédica de Córdoba) ; Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD) ; Universitat Autònoma de Barcelona
Abstract Background: In first-line wild-type (WT)-Kirsten rat sarcoma viral oncogene homologue (KRAS) metastatic colorectal cancer (mCRC), panitumumab (Pmab) improves outcomes when added to FOLFOX [folinic acid, 5-fluorouracil, and oxaliplatin] or FOLFIRI [folinic acid, 5-fluorouracil, and irinotecan]. [...]
2017 - 10.1016/j.ejca.2017.04.024
European journal of cancer, Núm. 81 (2017) , p. 191-202  

¿Le interesa recibir alertas sobre nuevos resultados de esta búsqueda?
Defina una alerta personal vía correo electrónico o subscríbase al canal RSS.